Kalamazoo, Michigan, United States In 2003 was created Biosciences Research and Commercialization Center (BRCC), which is appeared as VC. The main office of represented VC is situated in the Kalamazoo. The fund was located in North America if to be more exact in United States. Biosciences Research and Commercialization Center (BRCC) appeared to be a CVC structure as part of the corporation.
Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Biotechnology, Clinical Trials. Among the most popular portfolio startups of the fund, we may highlight Ocuphire Pharma, Axonia Medical, ONL Therapeutics.
The fund is generally included in less than 2 deals every year. The high activity for fund was in 2019. The usual things for fund are deals in the range of 1 - 5 millions dollars.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Biosciences Research and Commercialization Center (BRCC), startups are often financed by Grand Angels, Southwest Michigan First, National Institutes of Health. The meaningful sponsors for the fund in investment in the same round are Grand Angels, Blue Water Angels, Invest Michigan. In the next rounds fund is usually obtained by Invest Michigan, Grand Angels, Muskegon Angels.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Airbnb | California, San Francisco, United States |
| American Heart Association | Dallas, Texas, United States |
| Anthill Studio | Andhra Pradesh, Hyderabad, India |
| Asia Africa Investment & Consulting | Central, Central Region, Singapore |
| Aviva Canada | Canada, Ontario, Toronto |
| Business Solutions | Horsham, Pennsylvania, United States |
| China Advanced Construction Materials | Beijing, Beijing, China |
| Clyde Blowers Capital | Scotland, South Lanarkshire, United Kingdom |
| EVA Precision Ind | - |
| Frutarom | Hefa, Hefa, Israel |
| Lexington Venture | Beverly Hills, California, United States |
| Namier Capital Partners | England, London, United Kingdom |
| Ningbo Huiya | China, Ningbo, Zhejiang |
| Orion Partners | China, Hong Kong, Hong Kong Island |
| Sylvan Learning | Hunt Valley, Maryland, United States |
| The Paradise Group | - |
| Three-Five Systems | Minneapolis, Minnesota, United States |
| Xinyu Canjin Touzi Hehuo Qiye (Youxian Hehuo) | China, Jiangxi, Xinyu |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
| $2M | 23 Feb 2021 | Michigan, United States | |||
ONL Therapeutics | $46M | 22 Dec 2020 | Ann Arbor, Michigan, United States | ||
Ocuphire Pharma | $5M | 22 Jul 2019 | Michigan, United States | ||
GreenMark Biomedical | $670K | 20 Mar 2019 | Michigan, United States | ||
Fifth Eye | $2M | 23 Jul 2018 | Ann Arbor, Michigan, United States | ||
GreenMark Biomedical | $500K | 29 Jun 2018 | Michigan, United States | ||
ONL Therapeutics | $4M | 17 May 2017 | Ann Arbor, Michigan, United States | ||
Tetra Discovery | $1M | 03 Sep 2015 | Grand Rapids, Michigan, United States | ||
Axonia Medical | $2M | 09 Jun 2014 | Kalamazoo, Michigan, United States |
– Asalyxa Bio closed a $2m seed financing round to advance its lead program into first-in-human clinical trials.
– The financing was led by Research Bridge Partners, co-led by ID Ventures, and also included Michigan Rise Pre-Seed Fund III, BRCC of Western Michigan University, Ann Arbor Spark, Woodward Angels and other undisclosed investors.
– Proceeds from the financing will be used to advance Asalyxa Bio’s lead development candidate, ASX-100, into first-in-human clinical trials.
– Asalyxa Bio’s drug development programs are based on the company’s proprietary PANTHER technology platform, which enables the targeted delivery of therapeutic compounds directly to neutrophils and other key immune cells.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
| $2M | 23 Feb 2021 | Michigan, United States | |||
ONL Therapeutics | $46M | 22 Dec 2020 | Ann Arbor, Michigan, United States | ||
Ocuphire Pharma | $5M | 22 Jul 2019 | Michigan, United States | ||
GreenMark Biomedical | $670K | 20 Mar 2019 | Michigan, United States | ||
Fifth Eye | $2M | 23 Jul 2018 | Ann Arbor, Michigan, United States | ||
GreenMark Biomedical | $500K | 29 Jun 2018 | Michigan, United States | ||
ONL Therapeutics | $4M | 17 May 2017 | Ann Arbor, Michigan, United States | ||
Tetra Discovery | $1M | 03 Sep 2015 | Grand Rapids, Michigan, United States | ||
Axonia Medical | $2M | 09 Jun 2014 | Kalamazoo, Michigan, United States |
